CSIMarket Company Name, Ticker, Suppliers, else..
 
Northwest Biotherapeutics Inc  (NONE: NWBO)
 

Northwest Biotherapeutics Inc's Suppliers Performance

NWBO's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
NWBO Costs vs Sales of Suppliers Growth

• More on NWBO Suppliers






Northwest Biotherapeutics Inc's Comment on Supply Chain


The company depends on manufacturing arrangements that may lead to increased costs and potential delays. Its Sawston facility serves as a primary production site, and any issues there could require establishing new production agreements, which may be difficult to obtain or unfavorable. Manufacturing DCVax product candidates involves complex processes that require specialized facilities, trained personnel, long lead times for equipment and training, and regulatory approvals. Alternative production capacity may not be readily accessible. Scaling up manufacturing for commercialization poses challenges, as neither the company nor its contract manufacturers have prior experience with such scale-up. The personalized nature of DCVax products, which consist of living cells, adds further complexity. Dendreon Corporation is cited as an example of a company that encountered difficulties scaling up manufacturing for its Provenge product.

Northwest Biotherapeutics Inc's Comment on Supply Chain


The company depends on manufacturing arrangements that may lead to increased costs and potential delays. Its Sawston facility serves as a primary production site, and any issues there could require establishing new production agreements, which may be difficult to obtain or unfavorable. Manufacturing DCVax product candidates involves complex processes that require specialized facilities, trained personnel, long lead times for equipment and training, and regulatory approvals. Alternative production capacity may not be readily accessible. Scaling up manufacturing for commercialization poses challenges, as neither the company nor its contract manufacturers have prior experience with such scale-up. The personalized nature of DCVax products, which consist of living cells, adds further complexity. Dendreon Corporation is cited as an example of a company that encountered difficulties scaling up manufacturing for its Provenge product.







NWBO's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Northwest Biotherapeutics Inc 262.79 2.17 -38.88 105
SUBTOTAL 0.00 0.00 0.00 -


Sources: Northwest Biotherapeutics Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Northwest Biotherapeutics Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.